167 related articles for article (PubMed ID: 22906006)
1. Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.
Niethammer AG; Lubenau H; Mikus G; Knebel P; Hohmann N; Leowardi C; Beckhove P; Akhisaroglu M; Ge Y; Springer M; Grenacher L; Buchler MW; Koch M; Weitz J; Haefeli WE; Schmitz-Winnenthal FH
BMC Cancer; 2012 Aug; 12():361. PubMed ID: 22906006
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.
Schmitz-Winnenthal FH; Hohmann N; Schmidt T; Podola L; Friedrich T; Lubenau H; Springer M; Wieckowski S; Breiner KM; Mikus G; Büchler MW; Keller AV; Koc R; Springfeld C; Knebel P; Bucur M; Grenacher L; Haefeli WE; Beckhove P
Oncoimmunology; 2018; 7(4):e1303584. PubMed ID: 29632710
[TBL] [Abstract][Full Text] [Related]
3. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study.
Suzuki N; Hazama S; Iguchi H; Uesugi K; Tanaka H; Hirakawa K; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Shimizu R; Hayashi H; Sakata K; Takenouchi H; Matsui H; Shindo Y; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Nakamura Y; Oka M; Nagano H
Cancer Sci; 2017 Jan; 108(1):73-80. PubMed ID: 27783849
[TBL] [Abstract][Full Text] [Related]
4. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
Bruns CJ; Shrader M; Harbison MT; Portera C; Solorzano CC; Jauch KW; Hicklin DJ; Radinsky R; Ellis LM
Int J Cancer; 2002 Nov; 102(2):101-8. PubMed ID: 12385004
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
Miyazawa M; Katsuda M; Maguchi H; Katanuma A; Ishii H; Ozaka M; Yamao K; Imaoka H; Kawai M; Hirono S; Okada KI; Yamaue H
Int J Cancer; 2017 Feb; 140(4):973-982. PubMed ID: 27861852
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.
Schmitz-Winnenthal FH; Hohmann N; Niethammer AG; Friedrich T; Lubenau H; Springer M; Breiner KM; Mikus G; Weitz J; Ulrich A; Buechler MW; Pianka F; Klaiber U; Diener M; Leowardi C; Schimmack S; Sisic L; Keller AV; Koc R; Springfeld C; Knebel P; Schmidt T; Ge Y; Bucur M; Stamova S; Podola L; Haefeli WE; Grenacher L; Beckhove P
Oncoimmunology; 2015 Apr; 4(4):e1001217. PubMed ID: 26137397
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.
Yamaue H; Tsunoda T; Tani M; Miyazawa M; Yamao K; Mizuno N; Okusaka T; Ueno H; Boku N; Fukutomi A; Ishii H; Ohkawa S; Furukawa M; Maguchi H; Ikeda M; Togashi Y; Nishio K; Ohashi Y
Cancer Sci; 2015 Jul; 106(7):883-90. PubMed ID: 25867139
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer.
Miyazawa M; Ohsawa R; Tsunoda T; Hirono S; Kawai M; Tani M; Nakamura Y; Yamaue H
Cancer Sci; 2010 Feb; 101(2):433-9. PubMed ID: 19930156
[TBL] [Abstract][Full Text] [Related]
9. A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer.
Suzuki N; Hazama S; Ueno T; Matsui H; Shindo Y; Iida M; Yoshimura K; Yoshino S; Takeda K; Oka M
J Immunother; 2014 Jan; 37(1):36-42. PubMed ID: 24316554
[TBL] [Abstract][Full Text] [Related]
10. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
12. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
14. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy.
Katsuda M; Miyazawa M; Ojima T; Katanuma A; Hakamada K; Sudo K; Asahara S; Endo I; Ueno M; Hara K; Yamada S; Fujii T; Satoi S; Ioka T; Ohira M; Akahori T; Kitano M; Nagano H; Furukawa M; Adachi T; Yamaue H
Trials; 2019 Apr; 20(1):242. PubMed ID: 31029154
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.
Kaida M; Morita-Hoshi Y; Soeda A; Wakeda T; Yamaki Y; Kojima Y; Ueno H; Kondo S; Morizane C; Ikeda M; Okusaka T; Takaue Y; Heike Y
J Immunother; 2011 Jan; 34(1):92-9. PubMed ID: 21150717
[TBL] [Abstract][Full Text] [Related]
16. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.
Kindler HL; Ioka T; Richel DJ; Bennouna J; Létourneau R; Okusaka T; Funakoshi A; Furuse J; Park YS; Ohkawa S; Springett GM; Wasan HS; Trask PC; Bycott P; Ricart AD; Kim S; Van Cutsem E
Lancet Oncol; 2011 Mar; 12(3):256-62. PubMed ID: 21306953
[TBL] [Abstract][Full Text] [Related]
17. Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.
Saif MW
JOP; 2008 Mar; 9(2):91-8. PubMed ID: 18326919
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer.
Matsuyama M; Ishii H; Furuse J; Ohkawa S; Maguchi H; Mizuno N; Yamaguchi T; Ioka T; Ajiki T; Ikeda M; Hakamada K; Yamamoto M; Yamaue H; Eguchi K; Ichikawa W; Miyazaki M; Ohashi Y; Sasaki Y
Invest New Drugs; 2015 Apr; 33(2):490-5. PubMed ID: 25502982
[TBL] [Abstract][Full Text] [Related]
19. Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT-BT trial).
Okusaka T; Ueno M; Sato T; Heike Y
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):314-8. PubMed ID: 22273718
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
Schultheis B; Reuter D; Ebert MP; Siveke J; Kerkhoff A; Berdel WE; Hofheinz R; Behringer DM; Schmidt WE; Goker E; De Dosso S; Kneba M; Yalcin S; Overkamp F; Schlegel F; Dommach M; Rohrberg R; Steinmetz T; Bulitta M; Strumberg D
Ann Oncol; 2017 Oct; 28(10):2429-2435. PubMed ID: 28961832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
